Scholarlink

Background <p>Visceral adipose tissue (VAT) is well established as a pathogenic fat depot, whereas superficial subcutaneous adipose tissue (SAT) is associated with either an improved or neutral cardiovascular state. However, it is unclear to what extent VAT area (VATcm<sup>2</sup>) and its proportion of total abdominal adipose tissue (VAT%) are distinguished in predicting cardiometabolic status and clinical outcomes during weight loss.</p> Methods <p>We integrated magnetic resonance imaging (MRI) measurements of VAT, deep-SAT, and superficial-SAT from two 18-month lifestyle weight loss clinical trials, CENTRAL and DIRECT&#xa0;PLUS (<i>n</i> = 572).</p> Results <p>At baseline, the mean VATcm<sup>2</sup> was 144.8cm<sup>2</sup> and VAT% = 28.2%; over 18&#xa0;months, participants lost 28cm<sup>2</sup> VATcm<sup>2</sup> (− 22.5%), and 1.3 VAT% units. Baseline VATcm<sup>2</sup> and VAT% were similarly associated with metabolic syndrome, hypertension, and diabetes status, while VAT% better classified hypertriglyceridemia. Conversely, higher VATcm<sup>2</sup> was associated with elevated high-sensitivity C-reactive protein (hsCRP), while VAT% was not. After 18&#xa0;months of lifestyle intervention, both VATcm<sup>2</sup> and VAT% loss were significantly associated with decreased triglycerides, HbA1c, ferritin, and liver enzymes, and increased HDL-c levels beyond weight loss (FDR &lt; 0.05). Only VATcm<sup>2</sup> loss was correlated with decreased HOMA-IR, chemerin, and leptin levels.</p> Conclusions <p>MRI follow-up of 572 participants over 18&#xa0;months of weight loss intervention suggests that although increased VATcm<sup>2</sup> and VAT% exhibit similar clinical manifestations, it might be preferable to examine VAT% when exploring lipid status, while VATcm<sup>2</sup> may better reflect inflammatory and glycemic states.</p> Trial registration <p>CENTRAL (Clinical-trials-identifier: NCT01530724); DIRECT&#xa0;PLUS (Clinical-trials-identifier: NCT03020186).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Visceral adipose tissue area and proportion provide distinct reflections of cardiometabolic outcomes in weight loss; pooled analysis of MRI-assessed CENTRAL and DIRECT PLUS dietary randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月4日

查看全文
  • Hadar Klein,
  • Hila Zelicha,
  • Anat Yaskolka Meir,
  • Ehud Rinott,
  • Gal Tsaban,
  • Alon Kaplan,
  • Yoash Chassidim,
  • Yftach Gepner,
  • Matthias Blüher,
  • Uta Ceglarek,
  • Berend Isermann,
  • Michael Stumvoll,
  • Ilan Shelef,
  • Lu Qi,
  • Jun Li,
  • Frank B. Hu,
  • Meir J. Stampfer,
  • Iris Shai

摘要

Background

Visceral adipose tissue (VAT) is well established as a pathogenic fat depot, whereas superficial subcutaneous adipose tissue (SAT) is associated with either an improved or neutral cardiovascular state. However, it is unclear to what extent VAT area (VATcm2) and its proportion of total abdominal adipose tissue (VAT%) are distinguished in predicting cardiometabolic status and clinical outcomes during weight loss.

Methods

We integrated magnetic resonance imaging (MRI) measurements of VAT, deep-SAT, and superficial-SAT from two 18-month lifestyle weight loss clinical trials, CENTRAL and DIRECT PLUS (n = 572).

Results

At baseline, the mean VATcm2 was 144.8cm2 and VAT% = 28.2%; over 18 months, participants lost 28cm2 VATcm2 (− 22.5%), and 1.3 VAT% units. Baseline VATcm2 and VAT% were similarly associated with metabolic syndrome, hypertension, and diabetes status, while VAT% better classified hypertriglyceridemia. Conversely, higher VATcm2 was associated with elevated high-sensitivity C-reactive protein (hsCRP), while VAT% was not. After 18 months of lifestyle intervention, both VATcm2 and VAT% loss were significantly associated with decreased triglycerides, HbA1c, ferritin, and liver enzymes, and increased HDL-c levels beyond weight loss (FDR < 0.05). Only VATcm2 loss was correlated with decreased HOMA-IR, chemerin, and leptin levels.

Conclusions

MRI follow-up of 572 participants over 18 months of weight loss intervention suggests that although increased VATcm2 and VAT% exhibit similar clinical manifestations, it might be preferable to examine VAT% when exploring lipid status, while VATcm2 may better reflect inflammatory and glycemic states.

Trial registration

CENTRAL (Clinical-trials-identifier: NCT01530724); DIRECT PLUS (Clinical-trials-identifier: NCT03020186).